Pete Griffin

Mr. Pete Griffin


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LPLorenzo Placidi
Lorenzo Placidi
PGPete Griffin
Pete Griffin
RCRoberta Castriconi
Roberta Castriconi
ATAlessia Tudda
Alessia Tudda
GBGiovanna Benecchi
Giovanna Benecchi
Claudio FiorinoClaudio Fiorino
Claudio Fiorino
Background: Knowledge-based (KB) planning is a promising approach to model prior planning experience and optimize radiotherapy. To enable the sharing of models across institutions, their transferability must be evaluated. This study aimed to validate KB prediction models developed by a national consortium using data from another multi-institutional consortium in a different country. Methods: Ten right whole breast tangential field (RWB-TF) models were built within the national consortium. A cohort of 20 patients from the external consortium was used for testing. Transferability was defined when the ipsilateral (IPSI) lung first principal component (PC1) was within the 10th–90th percentile of the training set. Predicted dose–volume parameters were compared with clinical dose–volume histograms (cDVHs). Results: Planning target volume (PTV) coverage strategies were comparable between the two consortia, even though significant volume differences were observed for the PTV and contralateral breast (p = 0.002 and p = 0.02, respectively). For the IPSI lung, the standard deviation of predicted mean dose/V20 Gy was 1.13 Gy/2.9% in the external consortium versus 0.55 Gy/1.6% in the training consortium. Differences between the cDVH and the predicted IPSI lung mean dose and the volume receiving more than 20 Gy (V20 Gy) were <2 Gy and <5% in 88.7% and 92.3% of cases, respectively. PC1 values fell within the 10th–90th percentile for ≥90% of patients in 6/10 models and 65–85% for the remaining 4. Conclusions: This study demonstrates the feasibility of applying RWB-TF KB models beyond the consortium in which they were developed, supporting broader clinical implementation. This retrospective study was supported by AIRC (Associazione Italiana per la Ricerca sul Cancro) and registered on ClinicalTrials.gov (NCT06317948, 12 March 2024).